Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1

Clinical Cancer Research

Volumn 11, Issue 4, 2005, Pages 1639-1649

  Tseng, Sheng Hong ^a   Chen, Yun ^a,c   Chang, Chun Jung ^b   Tai, Kuo Feng ^b   Lin, Swei Ming ^a   Hwang, Lih Hwa ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; B7.1 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETROVIRUS VECTOR; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL SELECTION; CELL STRAIN RT 2; CONTROLLED STUDY; DRUG EFFECT; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC ENGINEERING; GLIOMA CELL; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL TIME; T LYMPHOCYTE; TUMOR GROWTH; VIRUS RECOMBINANT;

ANIMALS; ANTIGENS, CD80; APOPTOSIS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; GENETIC VECTORS; GLIOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; RATS; RETROVIRIDAE; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TIME FACTORS; TRANSFECTION;

EID: 14644437735     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1366     Document Type: Article

References (68)

1. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas: a simple and reproducible method. Cancer 1988;62: 2152-65.
2. Kim TS, Halliday AL, Hedley-Whyte ET, Convery K. Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg 1991;74:27-37.
3. Mahaley MS Jr, Mettlin C, Natarajan N, Laws ER Jr, Peace B. National survey on patterns of care for brain-tumor patients. J Neurosurg 1989;71:826-36.
4. Salazar OM, Rubin P, Feldstein ML, Pizzutiello R. High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys 1979;5:1733-40.
5. Walker MD, Green SB, Byar DR, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-9.
6. Brooks WH, Netsky MG, Normansell DE, Horwitz DA. Depressed cell-mediated immunity in patients with primary intracranial tumors: characterization of a humoral immunosuppressive factor. J Exp Med 1972;136:1631-47.
7. Couldwell WT, Dore-Duffy P, Apuzzo MLJ, Antel JP. Malignant glioma modulation of immune function: relative contribution of different soluble factors. J Neuroimmunol 1991;33:89-96.
8. Mahaley MS, Brooks WH, Roszman TL, Bigner DD, Duka L, Richardson S. Immunobiology of primary intracranial tumors. Part I. Studies of the cellular and humoral general immune competence of the brain-tumor patients. J Neurosurg 1977;46:467-76.
9. Roszman T, Elliott L, Brooks W. Modulation of T-cell function by gliomas. Immunol Today 1991;12:370-4.
10. Ram Z, Walbridge S, Heiss JD, Culver KW, Blaese RM, Oldfield EH. In vivo transfer of the human interleukin-2 gene: negative results in experimental brain tumors. J Neurosurg 1994;80:535-40.
11. + cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci U S A 1996;93:10399-404.
12. Tseng SH, Hwang LH, Lin SM. Induction of antitumor immunity by intracerebrally implanted rat C6 glioma cells genetically engineered to secrete cytokines. J Immunother 1997;20:334-42.
13. Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K, Hamada H. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 1996;56:1823-33.
14. Yu JS, Wei MX, Chiocca EA, Martuza RL, Tepper RI. Treatment of glioma by engineered interleukin-4-secreting cells. Cancer Res 1993;53: 3125-8.
15. Cayeux S, Beck C, Dorken B, Blankenstein T. Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant. Hum Gene Ther 1996;7:525-9.
16. Kikuchi T, Joki T, Abe T, Ohno T. Antitumor activity of killer cells stimulated with both interleukin-2 and interleukin-12 on mouse glioma cells. J Immunother 1999;22:245-50.
17. Tseng SH, Hsieh CL, Lin SM, Hwang LH. Regression of orthotopic brain tumors by cytokine-assisted tumor vaccines primed in the brain. Cancer Gene Ther 1999;6:302-12.
18. Zitvogel L, Robbins PD, Storkus WJ, et al. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 1996;26: 1335-41.
19. Chong H, Todryk S, Hutchinson G, Hart IR, Vile RG. Tumor cell expression of B7 costimulatory molecules and interleukin-12 of granulocyte-macrophage colony-stimulating factor induces a local antitumor response and may generate systemic protective immunity. Gene Ther 1998;5:223-32.
20. Colombo MP, Forni G. Immunotherapy 1. Cytokine gene transfer strategies. Cancer Metastasis Rev 1996;15:317-28.
21. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993;11: 191-212.
22. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994;5:153-64.
23. Ward SG. CD28: a signaling perspective. Biochem J 1996;6:361-77.
24. Chen L, McGowan P, Ashe S, Johnston JV, Hellstrom I, Hellstrom KE. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res 1994;54:5420-3.
25. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995;13:399-415.
26. Bain C, Merrouche Y, Puisieux I, Duc A, Colombo MP, Favrot M. B7.1 gene transduction of human renal-cell carcinoma cell lines restores the proliferative response and cytotoxic function of allogenic cells. Int J Cancer 1996;67:769-76.
27. Habicht A, Lindauer M, Galmbacher P, et al. Development of immunogenic colorectal cancer cell lines for vaccination: expression of CD80 (B7.1) is not sufficient to restore impaired primary T cell activation in vitro. Eur J Cancer 1995;31A:2396-402.
28. Townsend SE, Su FW, Atherton JM, Allison JP. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 1994;54:6477-83.
29. Wendtner CM, Nolte A, Mangold E, et al. Gene transfer of costimulatory molecule B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene Ther 1997;4:726-35.
30. Wu TC, Huang AYC, Jaffee EM, Levitsky HI, Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995;182:1415-21.
31. Abbas AK, Lichtman AH, Pober JS. T lymphocyte antigen recognition and activation. In: Abbas AK, Lichtman AH, Pober JS, editors. Cellular and molecular immunology. Philadelphia: W.B. Saunders Co.; 1997. p. 138-70.
32. Sun X, Vale M, Leung E, Kanwar JR, Gupta R, Krissansen GW. Mouse B7-H3 induces antitumor immunity. Gene Ther 2003;10: 1728-34.
33. Larsen CP, Ritchie SC, Hendrix R, et al. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol 1994;152: 5208-19.
34. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulate T cell proliferation and interleukin-2 mRNA accumulation. J Exp Med 1991;173:721-30.
35. Kruger M, Gool S, Peng XH, Coorevits L, Casteels-Vandaele M, Ceuppens JL. Production of granulocyte-macrophage colony-stimulating factor by T cells is regulated by B7 and IL-1β. Immunology 1996;88:49-54.
36. Kim SH, Carew JF, Kooby DA, et al. Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer. Cancer Gene Ther 2000;7:1279-85.
37. Mukherjee S, Nelson D, Loh S, et al. The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor. Cancer Gene Ther 2001;8:580-8.
38. Stripecke R, Skelton DC, Pattengale PK, Shimada H, Kohn DB. Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia. Hum Gene Ther 1999;10:2109-22.
39. Sumimoto H, Tani K, Nakazaki Y, et al. Superiority of interleukin-12 transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice. Cancer Gene Ther 1998;5:29-37.
40. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 1988;62:1120-4.
41. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988;67:400-6.
42. Copeland DD, Talley FA, Bigner DD. The fine structure of intracranial neoplasms induced by the inoculation of avian sarcoma virus in neonatal and adult rats. Am J Pathol 1976;83:149-76.
43. Hsieh CL, Chen BF, Wang CC, Liu HH, Chen DS, Hwang LH. Improved gene expression by a modified bicistronic retroviral vector. Biochem Biophys Res Commun 1995;214:910-7.
44. Hsieh CL, Pang VF, Chen DS, Hwang LH. Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: implications for cytotoxic T lymphocyte responses and tumor burdens. Hum Gene Ther 1997;8:1843-54.
45. Weizsaecker M, Deen DF, Rosenblum ML, Hoshino T, Gutin PH, Barker M. The 9L rat brain tumor: description and application of an animal model. J Neurol 1981;224:183-92.
46. + T cells become nonresponsive (anergic) following activation in the presence of costimulation. J Immunol 1999;163:102-10.
47. Jenkins MK. The ups and downs of T cell costimulation. Immunity 1994;1:443-6.
48. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994;15:321-31.
49. L on activated T cells and can be prevented by CD28 costimulation. J Immunol 1998;158:598-603.
50. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996;183:2533-40.
51. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-7.
52. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996;183:2541-50.
53. + T cell mobilization/memory development and humoral immunity: comparison of αOX-40 with αCTLA-4. J Immunol 2001;167:6804-11.
54. + T cell apoptosis. J Infect Dis 2002;185:1077-93.
55. L. Immunity 1995;3:87-98.
56. Fraser JD, Irving BA, Crabtree GR, Weiss A. Regulation of IL-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991;251:313-6.
57. Lindstein T, June CH, Ledbetter JA, Stella G, Thompson CB. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 1989;244:339-43.
58. McLeod JD, Walker LSK, Patel YI, Boulougouris G, Sansom DM. Activation of human T cells with suppression (staphylococcal enterotoxin B) and CD28 confers resistance to apoptosis via CD95. J Immunol 1998;160:2072-9.
59. Greenfield E, Nguyen K, Kuchrno V. CD28/B7 costimulation: a review. Crit Rev Immunol 1998;18:389-418.
60. + T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin. J Leukoc Biol 2002;72:921-31.
61. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997;7:445-50.
62. Campanelli AP, Martins GA, Souto JT, et al. Fas-Fas ligand (CD95-CD95L) and cytotoxic T lymphocyte antigen-4 engagement mediate T cell unresponsiveness in patients with paracoccidioidomycosis. J Infect Dis 2003;187:1496-505.
63. + T cells. J Exp Med 1998;188: 1849-57.
64. Gribben JG, Freeman GJ, Boussiotis VA, et al. CTLA-4 mediates antigen-specific apoptosis of human T-cells. Proc Natl Acad Sci U S A 1995;92:811-5.
65. Wells AD, Li XC, Li Y, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999;5: 1303-7.
66. + T cell responses. Proc Natl Acad Sci U S A 1999;96:8603-8.
67. Sotomayor EM, Borrello 1, Tubb E, Allison JP, Levitsky HI. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A 1999;96:11476-81.
68. Yu X, Fourneir S, Allison JP, Sharpe AH, Hodes RJ. The role of B7 costimulation in CD4/CD8 T cell homeostasis. J Immunol 2000;164: 3543-53.